NO20012027L - Fremgangsmåter og blandinger for selektiv kreft-kjemoterapi - Google Patents

Fremgangsmåter og blandinger for selektiv kreft-kjemoterapi

Info

Publication number
NO20012027L
NO20012027L NO20012027A NO20012027A NO20012027L NO 20012027 L NO20012027 L NO 20012027L NO 20012027 A NO20012027 A NO 20012027A NO 20012027 A NO20012027 A NO 20012027A NO 20012027 L NO20012027 L NO 20012027L
Authority
NO
Norway
Prior art keywords
compositions
methods
cancer chemotherapy
selective cancer
vitamin
Prior art date
Application number
NO20012027A
Other languages
English (en)
Other versions
NO326995B1 (no
NO20012027D0 (no
Inventor
Raxit Jariwalla
Original Assignee
Oxycal Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxycal Lab Inc filed Critical Oxycal Lab Inc
Publication of NO20012027D0 publication Critical patent/NO20012027D0/no
Publication of NO20012027L publication Critical patent/NO20012027L/no
Publication of NO326995B1 publication Critical patent/NO326995B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20012027A 1999-08-30 2001-04-25 Anvendelse av plasmaloselig metalaskorbat og vitamin C metabolitter for fremstilling av en kreft-kjemoterapi blanding. NO326995B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/019449 WO2001015692A1 (en) 1999-08-30 1999-08-30 Methods and compositions for selective cancer chemotherapy

Publications (3)

Publication Number Publication Date
NO20012027D0 NO20012027D0 (no) 2001-04-25
NO20012027L true NO20012027L (no) 2001-06-20
NO326995B1 NO326995B1 (no) 2009-03-30

Family

ID=22273462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012027A NO326995B1 (no) 1999-08-30 2001-04-25 Anvendelse av plasmaloselig metalaskorbat og vitamin C metabolitter for fremstilling av en kreft-kjemoterapi blanding.

Country Status (16)

Country Link
US (1) US20040092549A1 (no)
EP (1) EP1124550B9 (no)
JP (1) JP2003508437A (no)
CN (1) CN1165301C (no)
AT (1) ATE401071T1 (no)
AU (1) AU783283B2 (no)
CA (1) CA2348565A1 (no)
CY (1) CY1108293T1 (no)
DE (1) DE69939123D1 (no)
DK (1) DK1124550T3 (no)
ES (1) ES2310941T3 (no)
NO (1) NO326995B1 (no)
NZ (1) NZ511396A (no)
PT (1) PT1124550E (no)
TW (1) TWI245643B (no)
WO (1) WO2001015692A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001280448B8 (en) * 1998-01-05 2008-05-29 The Ester C Company Vitamin C Compositions
US6878744B2 (en) * 1999-02-05 2005-04-12 Oxycal Laboratories, Inc. Vitamin C compositions
EP1282416A2 (en) * 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6468980B1 (en) * 2000-09-01 2002-10-22 Oxycal Laboratories, Inc. Methods and compositions for potentiating cancer chemotherapeutic agents
EP2859894A1 (en) * 2001-06-26 2015-04-15 The Ester C Company Vitamin C compositions
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
CN101506679B (zh) * 2006-08-18 2013-03-06 通用电气医疗集团股份有限公司 细胞死亡的13c-mr成像或波谱分析
WO2010043029A1 (en) * 2008-10-15 2010-04-22 Xingnong Wang Use of tetrose to inhibit cancer and to increase cell viability
WO2014070769A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
US20210283095A1 (en) * 2020-03-11 2021-09-16 Harold E. Siess Detection and Treatment of Viral Diseases and Cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822816A (en) * 1987-04-10 1989-04-18 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin C
GB2208798B (en) * 1987-07-20 1991-06-05 Norsk Hydro As Anti-cancer agent comprising l-ascorbic acid and o-benzylidene-l-ascorbic acid or deuterated derivative
WO1990012571A1 (en) * 1989-04-07 1990-11-01 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin c
WO1990003167A1 (en) * 1988-09-19 1990-04-05 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
KR100266373B1 (ko) * 1997-01-06 2000-09-15 더블유. 유 병 김치의 제조방법
PT982990E (pt) * 1998-02-06 2007-01-31 Ester C Company Composições líquidas estáveis de ascorbato de cálcio e métodos de preparação e utilização

Also Published As

Publication number Publication date
NZ511396A (en) 2003-08-29
CN1329489A (zh) 2002-01-02
AU783283B2 (en) 2005-10-13
TWI245643B (en) 2005-12-21
AU5785399A (en) 2001-03-26
DE69939123D1 (de) 2008-08-28
NO326995B1 (no) 2009-03-30
EP1124550A1 (en) 2001-08-22
ATE401071T1 (de) 2008-08-15
JP2003508437A (ja) 2003-03-04
WO2001015692A1 (en) 2001-03-08
EP1124550B1 (en) 2008-07-16
CN1165301C (zh) 2004-09-08
CA2348565A1 (en) 2001-03-08
EP1124550A4 (en) 2002-08-21
DK1124550T3 (da) 2008-11-17
EP1124550B9 (en) 2008-11-05
NO20012027D0 (no) 2001-04-25
PT1124550E (pt) 2008-08-29
CY1108293T1 (el) 2014-02-12
US20040092549A1 (en) 2004-05-13
WO2001015692A8 (en) 2001-10-11
ES2310941T3 (es) 2009-01-16

Similar Documents

Publication Publication Date Title
NZ526560A (en) Method of treating certain cancers using an estrogen agonist/antagonist
NO20012027L (no) Fremgangsmåter og blandinger for selektiv kreft-kjemoterapi
AU2003264068A1 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
MXPA04005435A (es) Metodo y composiciones para sellar una estructura tubular expandible en un pozo.
BR0207378A (pt) Tratamento de câncer
AU2003278534A1 (en) Ranging and positioning method and apparatus
GT200100008A (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
IL142720A0 (en) Water-miscible pharmaceutical compositions of paclitaxel
GB2358397A (en) Method of preparing delta-9-tetrahydrocannabinol esters
WO2001070243A3 (en) A method for treating early breast cancer
IL185921A0 (en) A process for the preparation of the 14beta-hydroxy-baccatin iii-1, 14-carbonate
HK1069170A1 (en) A process for the preparation of the 14beta-hydroxy-baccatin iii-1, 14-carbonate
ATE276766T1 (de) Chemotherapeutische zusammensetzung und verfahren
UA43624A (uk) Спосіб хіміотерапії раку яєчників
Chadwick Aitik plans for the Twentyfirst century
UA49562A (uk) Спосіб профілактики лімфогенних метастазів
ZA200308829B (en) "The provision of support in underground mine workings".
UA10740A (uk) Спосіб комбіhоваhого лікуваhhя раку шлуhку
ZA200101950B (en) Provision of support in underground mine workings.
WO2001026684A3 (en) Method for treating hypoxic cells
ES1047674U (es) Cabina-multimedia para mobiliario urbano dotada de todo tipo de servicios publicos en un solo conjunto.
WO2000078359A3 (en) Compositions for treating chemotherapy-resistant tumor cells
UA49523A (uk) Спосіб хіміотерапії раку шийки матки
UA22014A (uk) Спосіб відвалоутвореhhя в зоhі обвалеhhя

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees